The Ebris Foundation was born in 2012 from a joint initiative of the Fondazione Scuola Medica Salernitana and the Massachusetts General Hospital (MGH), teaching affiliate of Harvard Medical School, one of the most prestigious universities in the world. While the Fondazione Scuola Medica Salernitana aims to promote the scientific and cultural values and traditions of the ancient Salerno Medical School, the MGH is an internationally recognized teaching and research hospital.
Chaired by Alessio Fasano, a researcher recognized and appreciated all over the world for his expertise in gut microbiome and its impact on human health and professor of Pediatrics, Gastroenterology and Nutrition at the MGH for Children, the Foundation has become over the years a center of national and international excellence completely dedicated to multidisciplinary scientific research. Furthermore, Dr. Giulio Corrivetti, Vice President of the EBRIS Foundation, is a nationally recognized expert in human behavior.
In its laboratories equipped with cutting-edge and sophisticated instruments, the EBRIS Foundation carries out research activities of excellence. These focus on the in-depth analysis of the interaction between nutrition and health, i.e. the mechanisms by which nutrition is able to influence the pathogenesis of autoimmune diseases and some diseases of the nervous system.
Research and study activities involve multidisciplinary teams of high profile doctors, scientists and researchers from major international research institutions, who cooperate in order to understand the molecular basis of human diseases and translate laboratory discoveries into new diagnostic and therapeutic targets and drug delivery systems that can not only improve the quality of life of patients but go towards the overall well-being of humankind.
Celiac disease, diabetes, autism, cancer therapies, neurosciences are just some of the research projects in which the Foundation is involved: all are oriented towards the identification of innovative therapeutic protocols and above all strategies for the prevention of the most widespread diseases of our time.
The Ebris Foundation is a partner of the Endotarget project funded by the European Union. In this project, we aim to explore the relationship between gut microbiota, intestinal permeability, and systemic endotoxemia.
We are involved as coordinator of multicentre clinical trial on the efficacy of larazotide in combination with methotrexate in patients with untreated Rheumatoid Arthritis. The clinical trial wiil consist in a randomized, triple-blind, placebo-controlled, multicentre study, with 1:1 parallel assignment and cluster sampling by three participating centre (iMM, HUS, UNICAM).